Alana Welm
Affiliations: | Oncological Sciences | University of Utah, Salt Lake City, UT |
Area:
Oncology, Molecular Biology, ImmunologyGoogle:
"Alana Welm"Children
Sign in to add trainee| Henok Eyob | grad student | 2013 | University of Utah |
| Kelsi L. Andrade | grad student | 2014 | University of Utah |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Goddard ET, Linde MH, Srivastava S, et al. (2024) Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 42: 119-134.e12 |
| Cannon-Albright LA, Stevens J, Teerlink CC, et al. (2023) A Rare Variant in (rs111879470) Is Associated with Predisposition to Recurrent Breast Cancer in an Extended High-Risk Pedigree. Cancers. 15 |
| Wu Y, Chen S, Yang X, et al. (2023) Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Research. 83: 4161-4178 |
| Hermida-Prado F, Xie Y, Sherman S, et al. (2023) Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer Research |
| Quail DF, Park M, Welm AL, et al. (2023) Breast Cancer Immunity: It is TIME for the Next Chapter. Cold Spring Harbor Perspectives in Medicine |
| Petrosyan V, Dobrolecki LE, LaPlante EL, et al. (2022) Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts. Npj Breast Cancer. 8: 104 |
| Nandi A, Debnath R, Nayak A, et al. (2022) Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer. Cancer Research |
| Hoover AR, Liu K, DeVette CI, et al. (2022) Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clinical and Translational Medicine. 12: e937 |
| Kumar S, Nandi A, Singh S, et al. (2022) Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nature Communications. 13: 3927 |
| Stires H, Bado I, Brown T, et al. (2022) Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. Npj Breast Cancer. 8: 75 |